Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Gains from Sales and Divestitures (2021 - 2024)

Apellis Pharmaceuticals filings provide 4 years of Gains from Sales and Divestitures readings, the most recent being $1.4 million for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Sales and Divestitures rose 39.8% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Dec 2024, up 39.8%, and an annual FY2024 reading of $1.4 million, up 39.8% over the prior year.
  • Gains from Sales and Divestitures hit $1.4 million in Q4 2024 for Apellis Pharmaceuticals, up from $1.0 million in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $1.4 million in Q4 2024, with the low at $129000.0 in Q4 2021.
  • Median Gains from Sales and Divestitures over the past 4 years was $691000.0 (2022), compared with a mean of $732500.0.
  • The sharpest move saw Gains from Sales and Divestitures skyrocketed 184.5% in 2022, then surged 39.8% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $129000.0 in 2021, then soared by 184.5% to $367000.0 in 2022, then skyrocketed by 176.57% to $1.0 million in 2023, then skyrocketed by 39.8% to $1.4 million in 2024.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $1.4 million, $1.0 million, and $367000.0 for Q4 2024, Q4 2023, and Q4 2022 respectively.